tradingkey.logo

BioNexus Gene Lab Corp

BGLC
查看詳細走勢圖
4.150USD
+0.050+1.22%
收盤 12/24, 13:00美東報價延遲15分鐘
7.46M總市值
虧損本益比TTM

BioNexus Gene Lab Corp

4.150
+0.050+1.22%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.22%

5天

+0.97%

1月

-5.90%

6月

+55.43%

今年開始到現在

+48.37%

1年

+70.78%

查看詳細走勢圖

TradingKey BioNexus Gene Lab Corp股票評分

單位: USD 更新時間: 2025-12-24

操作建議

BioNexus Gene Lab Corp當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名217/404位。機構持股佔比非常高,中期看,股價處於下降通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

BioNexus Gene Lab Corp評分

相關信息

行業排名
217 / 404
全市場排名
407 / 4562
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

BioNexus Gene Lab Corp亮點

亮點風險
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
業績增長期
公司處於發展階段,最新年度總收入9.51M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入9.51M美元
估值合理
公司最新PE估值-3.25,處於3年歷史合理位
活躍度降低
近期活躍度降低,過去20天平均換手率-0.96

BioNexus Gene Lab Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

BioNexus Gene Lab Corp簡介

BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
公司代碼BGLC
公司BioNexus Gene Lab Corp
CEOTan (Lee Su-Leng)
網址https://www.bionexusgenelab.com/

常見問題

BioNexus Gene Lab Corp(BGLC)的當前股價是多少?

BioNexus Gene Lab Corp(BGLC)的當前股價是 4.150。

BioNexus Gene Lab Corp 的股票代碼是什麼?

BioNexus Gene Lab Corp的股票代碼是BGLC。

BioNexus Gene Lab Corp股票的52週最高點是多少?

BioNexus Gene Lab Corp股票的52週最高點是15.600。

BioNexus Gene Lab Corp股票的52週最低點是多少?

BioNexus Gene Lab Corp股票的52週最低點是2.007。

BioNexus Gene Lab Corp的市值是多少?

BioNexus Gene Lab Corp的市值是7.46M。

BioNexus Gene Lab Corp的淨利潤是多少?

BioNexus Gene Lab Corp的淨利潤為-1.60M。

現在BioNexus Gene Lab Corp(BGLC)的股票是買入、持有還是賣出?

根據分析師評級,BioNexus Gene Lab Corp(BGLC)的總體評級為--,目標價格為--。

BioNexus Gene Lab Corp(BGLC)股票的每股收益(EPS TTM)是多少

BioNexus Gene Lab Corp(BGLC)股票的每股收益(EPS TTM)是-1.278。
KeyAI